Trial Profile
A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Recombinant human serum albumin (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors R-Tech Ueno Ltd
- 15 Nov 2013 Phase I has been completed, according to a media release.
- 15 Nov 2013 New trial record